12 November2026: Enhertu sNDA submitted in Japan for HER2-expressing Uterine carcinosarcoma
Daiichi Sankyo has submitted a supplemental New Drug Application to Japan’s MHLW for Enhertu for patients with HER2-expressing (IHC 1+, 2+ or 3+) advanced or recurrent uterine carcinosarcoma, seeking to expand the ADC into this rare and aggressive gynecological cancer
The submission is supported by the investigator-initiated phase 2 STATICE trial, in which Enhertu demonstrated durable responses in previously chemotherapy-treated patients across different levels of HER2 expression. The study enrolled 34 patients and was the first prospective trial to demonstrate clinical activity of a HER2-directed therapy in uterine carcinosarcoma
The application addresses a significant unmet need in uterine carcinosarcoma, an aggressive and rare form of endometrial cancer associated with poor prognosis and high recurrence rates. Currently, treatment relies largely on chemotherapy, with recurrence reported in 57% of patients, highlighting the need for targeted treatment approaches, particularly in the advanced or recurrent setting
Enhertu is a HER2-directed ADC comprising a monoclonal antibody linked to multiple DXd topoisomerase I inhibitor payloads through cleavable tetrapeptide-based linkers. Its tumor-agnostic approach enables targeted cytotoxic delivery to HER2-overexpressing tumor cells across different tissue origins
Strategically, the application extends Enhertu’s tumor reach beyond breast, gastric, lung and other solid tumors into a rare gynecological malignancy, further demonstrating the potential of HER2 expression as a therapeutic biomarker across histologies. If approved, Enhertu could provide a targeted treatment option in a setting where chemotherapy remains the main systemic approach, while reinforcing Daiichi Sankyo’s tumor-agnostic ADC strategy